The long-awaited ‘Aviva Arena’ is set to open in 2028

A new stop-motion film is giving a sneak peek into the future of Bristol’s long-awaited arena. The 20,000-capacity venue, which will be called Aviva Arena after a major deal with insurance giant Aviva earlier this year, is being built by Malaysia-based YTL and is expected to open in late 2028.

It will be the first of its kind in the West Country and will host more than 120 major events each year when it opens.

The venue is being built at Brabazon, on the old Filton Airfield in South Gloucestershire, and will be part of a huge entertainment complex, called YTL Live, that will also include conference and exhibition space.

Some 1.4 million people a year are expected to attend live music, sports and entertainment events at the arena when it opens and in its first decade it is predicted to contribute an estimated £1bn to the wider Bristol economy.

Now a new film has been released, featuring a hand-crafted scale model of the venue to showcase what it will look like.

Andrew Billingham, chief executive of YTL Live, said the Bristol-made model brings YTL’s “vision to life in a unique and engaging way”.

“Aviva Arena represents a once-in-a-generation opportunity to create a world-class destination for live entertainment in the South West of England,” he said.

“This film offers an exciting glimpse of what’s to come, helping people visualise the scale, ambition and energy of the venue years before the doors open.”

YTL first announced plans for the Bristol Arena in 2018 after Bristol City Council abandoned earlier proposals to build a council-funded arena at Temple Island in the city centre.

But the Filton-based arena has been hampered by years of delays, with YTL admitting in 2023 there had been “challenges” caused by the Covid pandemic.

Phoebe Barter, Aviva’s Group brand director, said the venue would become “a landmark destination” for the South West of England.

“[It will transform] Bristol’s iconic Brabazon Hangars – birthplace of all the UK’s Concorde supersonic jets – into a state of-the-art live entertainment destination, together with the Aviva Stadium in Dublin and Aviva Studios in Manchester,” she said.

“It’s about bringing Aviva Arena to life now, well ahead of opening. Through the magic of stop motion film and a beautiful model crafted in Bristol, people can start to imagine the experiences it will deliver from late 2028 onwards – from iconic music and major sporting events to unforgettable shared moments that will define the venue for years to come.”

When it is finally finished, the Aviva Arena will be part of a wider development known as Brabazon New Town that includes thousands of homes, office space and a new train station.

It will also be at the heart of a corridor of connected developments in South Gloucestershire known as the West Innovation Arc.

Last year it was announced that Brabazon would receive town status from the government.

VanEck is a global asset management firm offering ETFs, mutual funds, private funds, model portfolios, institutional strategies, separately managed accounts, as well as UCITS funds. Since our founding in 1955, putting our clients’ interests first, in all market environments, has been at the heart of the firm’s mission. VanEck has a long history of looking beyond financial markets to spot trends that create meaningful investment opportunities. We were one of the first U.S. asset managers to give investors access to international markets, which set the tone for identifying asset classes and themes such as gold investing in 1968, emerging markets in 1993, and exchange traded funds in 2006 that later helped shape the investment industry. The firm oversees $161.7 billion in assets as of September 30, 2025. Disclosures: http://ow.ly/SZ9450N5qTJ.

A board meeting of Premier Explosives is scheduled for today.

Both Apollo Micro Systems and Premier Explosives are headquartered in Hyderabad. The proposed deal, if completed, would bring together two defence-focused companies at a time when India’s defence spending and exports are rising sharply.

Apollo Micro Systems makes defence equipment linked to India’s indigenisation and modernisation programmes. Its products include naval defence mines and components used in missile systems.

Premier Explosives makes explosives for defence and industrial use. Its products include TNT and propellants used in missiles. The company’s promoters own around a 40% stake. Their stake was recently transferred to a trust, as it was earlier held by promoters in their individual capacities.

Live Events

Also Read: TCS shares dip 2% ahead of Q1 earnings today. What can shareholders expect?
Apollo Micro Systems announced a Rs 3,200 crore fundraise earlier this week through the issue of shares and warrants to promoter and non-promoter entities. Several foreign portfolio investors, high net-worth individuals and funds are expected to participate in the funding.The proposed acquisition comes as private defence companies are drawing strong investor interest. India’s defence expenditure for 2026-27 is estimated at Rs 7.5 lakh crore, according to government data, about three times the level seen a decade ago. Defence exports have also crossed Rs 35,000 crore.

This has opened up opportunities for private companies in areas such as ammunition, explosives, missile components, electronics, drones, naval systems and aerospace manufacturing.

Several large private-sector groups have also stepped up their defence plans. Adani Defence and Aerospace has announced investments in the sector and recently inaugurated a project in Madhya Pradesh to manufacture TNT and propellants. Tata Group companies are also working through joint ventures with global defence majors such as Lockheed Martin and Boeing.

For Apollo Micro Systems, buying Premier Explosives would expand its presence from defence electronics and systems into explosives and propellants, giving it a wider role in the defence manufacturing chain.

The deal would also come at a time when the government is pushing domestic manufacturing in defence and seeking to reduce import dependence. Companies with approved products, manufacturing capacity and defence order pipelines are likely to remain in focus as spending rises.

(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times.)

In an exchange filing, the company said certain batches of semaglutide were found to be out of specification due to an issue associated with the API used in the product. It added that an investigation is underway to identify the root cause and that appropriate measures are being taken to ensure product quality.

Dr Reddy’s said commercial supplies of the product will be delayed until the issue is resolved. The company clarified that the development has no impact on patient safety or on the product’s existing global regulatory filings. It also reiterated its commitment to ensuring reliable global supplies of the metabolic therapy.

Also read: Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27Dr Reddy’s further said its management will host a conference call to discuss the development and answer questions from participants.

Live Events

The disclosure comes less than two months after Dr Reddy’s commercially launched its oral semaglutide tablet under the brand name Obeda in India for the treatment of type-2 diabetes. The once-daily oral drug is available in 3 mg, 7 mg and 14 mg strengths, priced at Rs 99, Rs 135 and Rs 225 per tablet, respectively.
The company had positioned the launch as a key milestone in building its GLP-1 portfolio after also becoming one of the first companies to launch a generic once-weekly injectable semaglutide in India following the expiry of the relevant patent earlier this year.

Dr Reddy’s Q4 snapshot

The pharma giant reported 86% year-on-year (YoY) decline in consolidated net profit to Rs 221 crore for the January-March quarter of FY26, as against Rs 1,587 crore in the year-ago period, leading to target price cuts by brokerages.
Its revenue from operations, meanwhile, fell 12% YoY to Rs 7,516 crore during the quarter under review, from Rs 8,506 crore reported in the corresponding quarter of the previous financial year.
Read more: Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in Canada

The decline in quarterly earnings was primarily on account of reduced sales of Lenalidomide, price erosion in North America and Europe Generics and a one-time SSA impact.

Dr Reddy’s share price has remained flat in 2026, up 2% YTD. In the last 5 years, the stock has delivered a return of 17%.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)